CRDF Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

105.56K

-30.09%

-0.189

-10.05%

80.00K

-26.61%

-0.180

-10%

80.00K

-33.88%

-0.182

-13.49%

Estimates Revision

The market is revising Upward the revenue expectations for Cardiff Oncology, Inc. (CRDF) for FY2025, with the revenue forecasts being adjusted by 6.56% over the past three months. During the same period, the stock price has changed by 39.37%.

Revenue Estimates for FY2025

Revise Upward

+6.56%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-7.92%

In Past 3 Month

Stock Price

Go Up

+39.37%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast CRDF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRDF is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

10.00

Averages

10.00

High

10.00

Current: 0.000

Low

10.00

Averages

10.00

High

10.00

Noble Capital

initiated

$12

2026-01-05

New

Reason

Noble Capital

Price Target

$12

2026-01-05

New

initiated

Reason

Noble Capital initiated coverage of Cardiff Oncology with an Outperform rating and $12 price target. Cardiff is developing onvansertib for the treatment of multiple cancer indications, with the lead program in metastatic colorectal cancer for patients with a mutation that makes the cancer more aggressive and difficult to treat, the analyst noted. The firm values shares based on estimated FY30 EPS of $2.30 per share, discounted at 30% per year to allow for clinical and regulatory risks, the analyst says.

H.C. Wainwright

Buy

downgrade

$18 -> $10

2025-08-06

Reason

H.C. Wainwright

Price Target

$18 -> $10

2025-08-06

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Cardiff Oncology to $10 from $18 and keeps a Buy rating on the shares following the Q2 report. The firm reduced its probability of approval for onvansertib to 25% from 40%, seeing a higher risk profile following the most recent data.

Ladenburg

Kevin Degeeter

Buy

initiated

$19

2025-07-08

Reason

Ladenburg

Kevin Degeeter

Price Target

$19

2025-07-08

initiated

Buy

Reason

Ladenburg analyst Kevin Degeeter initiated coverage of Cardiff Oncology with a Buy rating and $19 price target. The firm, which sees potential for onvansertib to become a new treatment option for first-line KRAS and NRAS mutated colorectal cancer, expects a planned update on July 29 to clarify the tolerability profile and potentially enable selection of an onvansertib dose for Phase 3 development.

Jefferies

Hold

initiated

$3.50

2025-06-24

Reason

Jefferies

Price Target

$3.50

2025-06-24

initiated

Hold

Reason

Jefferies initiated coverage of Cardiff Oncology with a Hold rating and $3.50 price target. The company's onvansertib has shown promising early data in 1L RAS mutations metastatic colorectal cancer, but the data are early and the drug's mechanism of action is risky with prior failed studies, the analyst tells investors in a research note. The firm believes catalysts for rest of year may not provide adequate efficacy insight. It plans to reassess the Hold rating post the July 29 data update.

H.C. Wainwright

Buy

maintain

$18

2025-06-19

Reason

H.C. Wainwright

Price Target

$18

2025-06-19

maintain

Buy

Reason

H.C. Wainwright says the "market overreaction" in shares of Cardiff Oncology "provides an attractive stock price entry point." Cardiff announced that it will now share updated clinical data from the CRDF-004 trial on July 29, as opposed to the prior guidance of the first half of 2025, driving an after-hours selloff of 13%, the analyst tells investors in a research note. H.C. Wainwright notes that during its discussion with management yesterday, the company disclosed the rationale for this slight delay is that the majority of the enrolled patients shall have at least two post-baseline scans by this time point. "This is a prudent and investor-conscious decision since it provides a more robust dataset and potentially removes the concern of unconfirmed responses," the firm contends. It reiterates a Buy rating on the shares with an $18 price target.

H.C. Wainwright

Robert Burns

Buy

upgrade

$17 -> $18

2025-05-09

Reason

H.C. Wainwright

Robert Burns

Price Target

$17 -> $18

2025-05-09

upgrade

Buy

Reason

H.C. Wainwright analyst Robert Burns raised the firm's price target on Cardiff Oncology to $18 from $17 and keeps a Buy rating on the shares following the Q1 report.

Valuation Metrics

The current forward P/E ratio for Cardiff Oncology Inc (CRDF.O) is -3.59, compared to its 5-year average forward P/E of -4.27. For a more detailed relative valuation and DCF analysis to assess Cardiff Oncology Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.27

Current PE

-3.59

Overvalued PE

-0.12

Undervalued PE

-8.42

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

640.62

Current PS

518.46

Overvalued PS

1076.15

Undervalued PS

205.10

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 901.42% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areBuying! The selling amount has increased 901.42% over the last month.

Sold

Bought

CRDF News & Events

Events Timeline

No data

News

9.0

2025-12-12Newsfilter

Oncolytics Biotech Secures FDA Approval for First Pancreatic Cancer Immunotherapy

9.0

2025-12-09NASDAQ.COM

Cardiff Unveils Phase 1 Results of Onvensertib for Chronic Myelomonocytic Leukemia at ASH 2025

9.0

2025-12-08Globenewswire

Cardiff Oncology Presents Onvansertib Efficacy Data at ASH Meeting, 40% Patient Response

People Also Watch

Frequently Asked Questions

What is Cardiff Oncology Inc (CRDF) stock price today?

The current price of CRDF is 3.08 USD — it has decreased -2.84 % in the last trading day.

What is Cardiff Oncology Inc (CRDF)'s business?

Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.

What is the price predicton of CRDF Stock?

What is Cardiff Oncology Inc (CRDF)'s revenue for the last quarter?

Cardiff Oncology Inc revenue for the last quarter amounts to 120.00K USD, decreased -27.27 % YoY.

What is Cardiff Oncology Inc (CRDF)'s earnings per share (EPS) for the last quarter?

Cardiff Oncology Inc. EPS for the last quarter amounts to -0.17 USD, decreased -32.00 % YoY.

What changes have occurred in the market's expectations for Cardiff Oncology Inc (CRDF)'s fundamentals?

How many employees does Cardiff Oncology Inc (CRDF). have?

Cardiff Oncology Inc (CRDF) has 32 emplpoyees as of January 10 2026.

What is Cardiff Oncology Inc (CRDF) market cap?

Today CRDF has the market capitalization of 207.47M USD.